BOSTON — Novo Nordisk has launched the Wegovy pill in the U.S., introducing the first oral GLP-1 medication approved by the Food and Drug Administration for chronic weight management and expanding patient choice in evidence-based obesity treatment.
The oral formulation marks a significant shift in obesity care by offering an alternative to injectable therapies, aimed at improving convenience and access for patients seeking long-term weight management solutions.
The launch coincides with an expanded NovoCare experience, designed to help patients identify trusted clinicians, better understand insurance coverage, and access ongoing support throughout their treatment journey. Through NovoCare, patients seeking FDA-approved obesity medications, including the newly launched Wegovy pill, can connect with recognized providers offering comprehensive, clinician-led metabolic care nationwide.
knownwell, a weight-inclusive primary care and metabolic health company that provides both virtual and in-person services, has been recognized as a NovoCare provider. Through this designation, patients exploring treatment with the Wegovy pill may be connected to knownwell’s multidisciplinary care model, which integrates medical, nutritional, and behavioral support through a national hybrid approach.
“The availability of the Wegovy pill represents an important evolution in obesity care — one that prioritizes convenience, choice, and meeting patients where they are,” said Brooke Boyarsky Pratt, CEO and co-founder of knownwell. “We’re excited to be part of this new movement and to support patients who are seeking effective treatment options paired with high-quality, insurance-covered care.”
knownwell’s clinical care is led by providers board-certified in obesity medicine and is structured to support patients beyond medication alone. The company emphasizes personalized treatment plans and ongoing engagement, offering both telehealth and in-person visits so patients can choose how and where they receive care.
“The Wegovy pill expands what’s possible for patients who may prefer or benefit from an oral option,” said Dr. Angela Fitch, chief medical officer and co-founder of knownwell. “When innovative medications are paired with consistent clinical care, education, and support, patients are better positioned to achieve meaningful and sustainable health outcomes.”
